GrundySMStoneNJBaileyALet al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. Circulation. Epub ahead of print 10 November 2018. DOI: 10.1161/CIR.0000000000000625.
2.
SabatineMSGiuglianoRPKeechACet al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
3.
SchwartzGGStegPGSzarekMet al.Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107.
4.
SbranaFDal PinoBBigazziFet al.Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: after PCSK-9 antibodies what else?Eur J Prev Cardiol2017; 24: 1528–1531.
5.
KaufmanTMWardenBAMinnierJet al.Application of PCSK9 inhibitors in practice. Circ Res2019; 124: 32–37.
6.
Reyes-SofferGPavlyhaMNgaiCet al.Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation2017; 135: 352–362.
7.
WattsGFChanDCSomaratneRet al.Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J2018; 39: 2577–2585.
8.
OoiEMWattsGFChanDCet al.Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol2015; 35: 2686–2693.
9.
O’DonoghueMLFazioSGiuglianoRPet al.Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER Trial. Circulation. Epub ahead of print 30 November 2018. DOI: 10.1161/CIRCULATIONAHA.118.037184.
10.
BittnerVSzarekMAylwardPEet al.Lp(a) and cardiovascular outcomes: an analysis from the ODYSSEY OUTCOMES Trial. Arterioscler Suppl2018; 32: 24–24.
11.
WilleitPRidkerPMNestelPJet al.Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet2018; 392: 1311–1320.
12.
WattsGFBoffaMB. Lipoprotein(a): lodestar for future clinical trials. Lancet2018; 392: 1281–1282.
13.
KojimaSShidaMYokoyamaH. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial2003; 7: 431–434.
14.
ZentiMGAltomariALupoMGet al.From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol2018; 25: 1843–1851.
MoriartyPMParhoferKGBabirakSPet al.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J2016; 37: 3588–3595.
17.
StiekemaLCAStroesESGVerweijSLet al.Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. Epub ahead of print 18 December 2018. DOI: 10.1093/eurheartj/ehy862.
18.
SafarovaMSEzhovMVAfanasievaOIet al.Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl2013; 14: 93–99.
19.
PokrovskySNAfanasievaOISafarovaMSet al.Specific Lp(a) apheresis: a tool to prove lipoprotein(a) atherogenicity. Atheroscler Suppl2017; 30: 166–173.
20.
StefanuttiCJuliusUWattsGFet al.Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol2017; 11: 858–871.
21.
VeljicIPolovinaMMilinkovicIet al.Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: do we have a vanquishing new strategy?Eur J Prev Cardiol2019; 26: 739–742.
22.
SbranaFDal PinoBBigazziFet al.Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled. Eur J Prev Cardiol. 2019; 26: 782.
